Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
CTD_human |
Angiotensin-converting enzyme genotype is associated with Alzheimer disease in the Japanese population.
|
10643899 |
1999 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
ACE genotypes associated with the risk of AD, but II genotype as risk genetic factor only restricted in subjects with high blood pressure.
|
12362316 |
2002 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme and alpha-2-macroglobulin gene polymorphisms are not associated with Alzheimer's disease in Colombian patients.
|
14759632 |
2004 |
Alzheimer's Disease
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
ACE-I/I homozygote corresponds to lower plasma ACE protein level and it is independently but less likely to be associated with AD.
|
21233092 |
2011 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme gene polymorphisms and risk for sporadic Alzheimer's disease: a meta-analysis.
|
24851853 |
2015 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic Alzheimer disease: evidence from an updated meta-analysis.
|
25360660 |
2014 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Angiotensin converting enzyme (ACE) is involved in proteolytic processing of the amyloid-β(Aβ) peptide implicated in the development of Alzheimer's disease (AD) and known products of ACE-based processing of Aβ42 are characterized by reduced aggregability and cytotoxicity.
|
30282362 |
2018 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
A deletion polymorphism at intron 16 of the ACE gene has also been associated with AD.
|
12480755 |
2002 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
A double-blind clinical trial should be considered to determine the effect of ACE inhibitors on prevention of AD in the context of ApoE genotype.
|
23948883 |
2013 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
A total of 400 healthy controls younger than 65 years and 350 patients with Alzheimer's disease (average age 72 years) were genotyped for the ACE and ecNOS polymorphisms.
|
10567488 |
1999 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
After a median survival time of 20.6 months, 85% from the ACE MCI converted to AD.
|
28269787 |
2017 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
LHGDN |
Alzheimer disease risk and genetic variation in ACE: a meta-analysis.
|
14872014 |
2004 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
CTD_human |
Alzheimer disease risk and genetic variation in ACE: a meta-analysis.
|
14872014 |
2004 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3.
|
19105203 |
2009 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
APO-E and ACE gene polymorphisms were carried out in the patient's group only to evaluate a possible association with known genetic risk factors for AD.
|
20213229 |
2010 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Association of Angiotensin-converting enzyme insertion(I)/deletion (D) genotype in Alzheimer's disease patients of north Indian population.
|
21770707 |
2011 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Cell-specific effects of ACE polymorphism are suggested, additional studies on neuronal cells might help to understand the role of this polymorphism in AD.
|
15722183 |
2005 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Cognitive phenotypes in Alzheimer's disease and genetic variants in ACE and IDE.
|
21232820 |
2012 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Critical review about all studies available on DCP1 genotyping and AD, age-associated cognitive decline, longevity, and other conditions revealed remarkable inconsistencies.
|
11992568 |
2002 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
CSF ACE1 weakly correlated with t-tau (r = 0.294, p = 0.066) and p-tau (r = 0.329, p = 0.038) but not with Aβ42 in the controls but not in AD.
|
31594235 |
2019 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
DNA polymorphisms of apolipoprotein B and angiotensin I-converting enzyme genes and relationships with lipid levels in Italian patients with vascular dementia or Alzheimer's disease.
|
9681639 |
1998 |
Alzheimer's Disease
|
0.900 |
Biomarker
|
disease |
BEFREE |
Finally, this paper discusses very recent biological evidence that further supports a role for ACE1 and hypothesises a number of readily testable mechanisms by which the ACE1 enzyme and other components of the renin-angiotensin-aldosterone system may be implicated in increased risk and/or the progression of AD.
|
12806589 |
2003 |
Alzheimer's Disease
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Further research is needed to elucidate any role that the DCP1 polymorphism may play in relation to Alzheimer's disease.
|
12605101 |
2003 |